Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Malignant Peripheral Nerve Sheath Tumor (MPNST)
100%
Neurofibromatosis Type 1 (NF-1)
83%
Neurofibromatosis Type I
73%
Tumor
41%
Sarcoma
38%
Plexiform Neurofibroma
30%
Soft Tissue Sarcoma
27%
Phase I Study
23%
Chemotherapy
18%
Tyrosine Kinase 2 (TYK2)
15%
Tumor Growth
15%
Osteoclast
13%
Bone Metastasis
12%
Overall Survival
12%
Clinical Trials
11%
Whole Exome Sequencing
11%
Cell-free DNA (cfDNA)
11%
Phase II Trial
10%
Metastasis
10%
Metastatic Soft Tissue Sarcoma
10%
Schwann Cells
9%
Peripheral Nerve Sheath Tumor
9%
Targeted Therapy
9%
Tumor Progression
9%
Bone Tumor
8%
Cutaneous Neurofibroma
8%
Histology
8%
Malignancy
8%
Tumor Cells
8%
MEK Inhibition
8%
Clinical Benefit Rate
8%
Rhabdomyosarcoma
8%
Neurofibromatosis Type 2
7%
Tumor Suppressor
7%
Ifosfamide
7%
Clinical Outcomes
7%
MEK Inhibitor (MEKi)
7%
Soft Tissue Tumor
7%
Overexpression
7%
Protein Expression
7%
Pazopanib
7%
Investigational Agents
7%
Bone Sarcoma
7%
Stable Disease
6%
C-X-C Chemokine Receptor Type 4 (CXCR4)
6%
Granular Cell Tumor
6%
Pulmonary Metastasis
6%
Fusion-negative Rhabdomyosarcoma
6%
Immortalization
6%
Neurofibromatosis
6%
Medicine and Dentistry
Malignant Peripheral Nerve Sheath Tumor
61%
Neurofibromatosis Type I
55%
Connective Tissue Cancer
40%
Plexiform Neurofibroma
32%
Tumor
30%
Neoplasm
27%
Soft Tissue Sarcoma
25%
Chemotherapy
22%
Genetics
18%
Diseases
16%
Cancer
13%
Overall Survival
13%
Arm
11%
Peripheral Nerve
11%
Clinical Trial
11%
Targeted Therapy
11%
Progression Free Survival
10%
Nerve Sheath Tumor
10%
Pathogenesis
8%
Pediatrics
8%
Ifosfamide
8%
Rhabdomyosarcoma
8%
Precursor
7%
Cell-Free DNA
7%
Metastatic Carcinoma
7%
Schwann Cell
7%
Treatment Option
7%
Protein Expression
7%
Tumor Progression
6%
Protein Tyrosine Kinase
6%
Bone Metastasis
6%
Granular Cell Tumor
6%
Transcriptional Regulator ATRX
6%
Neuro-Oncology
6%
Neurofibromatosis
6%
4 Iodo 2,5 Dimethoxyamphetamine
6%
Signal Transduction
6%
Magnetic Resonance Imaging
6%
Adverse Event
6%
Leiomyosarcoma
6%
Schwannomatosis
6%
Tumor Microenvironment
6%
Quality of Life
5%
MEK Inhibitor
5%
Mammalian Target of Rapamycin
5%
Malignant Transformation
5%
Histology
5%
Protein P53
5%
Malignant Neoplasm
5%
Biological Marker
5%